Provided by Integrity Continuing Education, Inc.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit ww.lillygrantoffice.com
Supported by an educational grant from Pfizer, Inc.
David Hunter MBBS, PhD, FRACP
Florance and Cope Chair of Rheumatology, Professor of Medicine
University of Sydney and Royal North Shore Hospital
Osteoarthritis (OA) is the most common form of arthritis, affecting an estimated 30.8 million Americans, and the prevalence of OA is increasing. The pathology of OA involves the entire joint, including cartilage degradation, bone remodeling, osteophyte formation, and synovial inflammation, which lead to pain, stiffness, swelling, and loss of normal joint function. The most commonly affected joints are the knees, hips, and hands. As a substantial contributor to disability worldwide, patients with OA experience chronic pain, loss of function, and decreased quality of life.
As a chronic disease frequently compounded by multiple comorbidities, OA management is complex and relies on a combination of pharmacological and nonpharmacological interventions. Unfortunately, the majority of patients with OA receive suboptimal therapy, and typical management is best characterized as palliative and reactive rather than coordinated, proactive, and preventative. This program highlights recent data presented at #ACR20, seeking to improve the care of patient with OA by providing leaners with the most up-to-date information about pharmacologic interventions for OA and OA pain.
This program is intended for rheumatologists, pain specialists, orthopedic surgeons, primary care physicians (PCPs), radiologists, pharmacists, psychologists, physical therapists, nurse practitioners, physician assistants, and other healthcare professionals (HCPs) that manage patients with osteoarthritis pain (OA) and chronic pain associated with OA.
Virtual Poster Session #2: Updates on the Evidence-Based Management of Osteoarthritis and Osteoarthritis Pain: Recent Guidelines and Emerging Therapies
ABSTRACT NUMBER: 1640
Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab: Pooled Analysis from International Studies
ABSTRACT NUMBER: 1641
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
ABSTRACT NUMBER: 1642
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2020 through November 20, 2021, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Integrity Continuing Education, Inc designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education, Inc requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
David Hunter, MD
Consulting Fees: Taiwan Liposome Biopharmaceuticals and Kolon TissueGene
Patima Tanapat, PhD hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc, you may be asked for your name, degree(s), affiliation(s), street address, telephone number, and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.